Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer

Showing 15 posts of 894 posts found.

Pfizer’s Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism

May 17, 2019
Medical Communications, Sales and Marketing FDA, Fragmin, Pfizer, pharma

The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to …

News

Pfizer’s abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis

May 16, 2019
Research and Development Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that …

News

Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

May 15, 2019
Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma

The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …

News

Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua

May 8, 2019
Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma

Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …

News

FDA approves first two drugs for transthyretin amyloid cardiomyopathy

May 7, 2019
Manufacturing and Production, Sales and Marketing FDA, Pfizer, US, Vyndamax, Vyndaqel, pharma

The FDA has approved its first two therapies for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), …

News
merck-keytruda

Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer

April 23, 2019
Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma

MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …

News
dmitry_nuyten

Pfizer immune-oncology leader joins Aduro Biotech as new CMO

April 23, 2019
Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology

Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, …

News

Pfizer unveils new Phase 2 data on 20-valent pneumococcal conjugate vaccine

April 15, 2019
Research and Development, Sales and Marketing Pfizer, Streptococcus pneumoniae, Vaccine, pharma

Pfizer has revealed new Phase 2 data on its 20-valent pneumococcal conjugate vaccine candidate, known as PF-06482077 (20vPnC), detailing the …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

News

FDA approves Pfizer’s Ibrance for advanced male breast cancer

April 5, 2019
Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma

The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …

News

European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer

April 4, 2019
Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …

News

Sangamo and Pfizer’s gene therapy increases FVIII activity in severe haemophilia A in early study

April 3, 2019
Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma

Sangamo Therapeutics and Pfizer have unveiled new Phase 1/2 data for their jointly developed investigational gene therapy SB-525, demonstrating that …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz

This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …

News

Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial

March 20, 2019
Research and Development Merck KGaA, Pfizer, javelin, oncology, ovarian cancer

Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy …

News
ianread

Pfizer CEO Ian Read’s pay packet cut from $27.9m to $19.5m

March 15, 2019
Medical Communications CEO, Ian Read, Pfizer, compensation, pay packet, salary

Ian Read has seen his total compensation cut from a sum of $27.9 million in 2018 to $19.5 million this …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026